Pfizer employees are preparing for a mass deployment of the company’s Covid-19 vaccine. The UK became the first country to approve Pfizer’s vaccine. “I’m so, so happy that, you know, 2020 has been just awful and 2021 is going to be better. And help is on the way,” said Matt Hancock, Britain’s Health Secretary. Pfizer’s vaccine has yet to receive emergency use approval in the United States, but authorities plan to vaccinate 100 million Americans by the end of February 2021. To access the video in direct and exclusive from CNBC, subscribe to CNBC PRO: The UK this week became the first country to allow Pfizer’s coronavirus vaccine for emergency use, likely adding pressure on the Food and Drug US administration to do the same quickly. Granted, the US and UK look at vaccines differently. Pfizer had submitted data on its vaccine with BioNtech on an ‘rolling basis’ to the UK, meaning that regulators were able to review the data in real time and do so until there was have sufficient evidence to justify a formal authorization. Continuous review is a tool that regulators use to expedite the evaluation of promising drugs or vaccines. In the United States, the FDA will review all aspects of the data submitted in the application, including reviewing all safety information “to make sure there are no cracks” and that everything is. solid, ”said Dr Paul Offit, a voting member of the Advisory Committee on Vaccines and Related Biologics, which is due to review Pfizer’s vaccine on Dec. 10. “I don’t know what data the UK was working on. I know when the data goes to the FDA it’s big, ”said Offit, also director of the Vaccine Education Center at Children’s Hospital in Philadelphia. “When you talk about a trial involving 44,000 people, that’s a lot of clinical data.” He said when Merck submitted data from its rotavirus vaccine trial on 70,000 people, the pages generated could have exceeded the height of the Sears Tower. This building, now known as the Willis Tower, is a 1,450-foot skyscraper in Chicago. “The point being: it’s a lot of data,” Offit said. Pfizer submitted its data on the Covid vaccine to the FDA on November 20. The FDA has said it will allow a vaccine that is at least 50% safe and effective. The flu shot, by comparison, typically reduces the risk of getting the flu by 40% to 60% compared to people who aren’t vaccinated, according to the Centers for Disease Control and Prevention. The agency’s review of the vaccine is expected to take a few weeks, and public health officials expect the first doses of the vaccine to be distributed in as little as two weeks. Offit said he doesn’t think a US clearance around a week after the UK makes a difference when you talk about vaccinating hundreds of millions of people. Vaccinating anyone who wants a vaccine will likely take more than a year, he added. Moreover, the UK has come under heavy criticism for approving Pfizer’s vaccine so quickly. Dr Anthony Fauci, the country’s leading infectious disease specialist, told Fox News the UK had not looked at Pfizer’s data “carefully”. »Subscribe to CNBC TV:» Subscribe to CNBC: »Subscribe to CNBC Classic: Turn to CNBC TV for the latest stock news and analysis. From market futures to live price updates, CNBC is the global leader in business news. The News with Shepard Smith is a daily CNBC news podcast that provides in-depth, non-partisan coverage and perspective on the day’s most important stories. Available at 8:30 p.m. ET / 5:30 p.m. PT daily starting September 30: Connect with CNBC News Online Get the latest news: Follow CNBC on LinkedIn: Follow CNBC News on Facebook: Follow CNBC News on Twitter: Follow CNBC News on Instagram: #CNBC #CNBCTV.
#Pfizer #Prepares #Mass #Deployment #Covid19 #Vaccine #Approves #Emergency